These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 9633121)

  • 1. [The question of intermittent hormonal treatment of cancer of the prostate].
    Boca P
    Acta Urol Belg; 1998 May; 66(2):17-20. PubMed ID: 9633121
    [No Abstract]   [Full Text] [Related]  

  • 2. The role of intermittent androgen deprivation in prostate cancer.
    Boccon-Gibod L; Hammerer P; Madersbacher S; Mottet N; Prayer-Galetti T; Tunn U
    BJU Int; 2007 Oct; 100(4):738-43. PubMed ID: 17662079
    [No Abstract]   [Full Text] [Related]  

  • 3. [Intermittent androgen blockade in prostatic carcinoma].
    Vachalovský V; Dvorácek J
    Cas Lek Cesk; 2002 Oct; 141(21):669-72. PubMed ID: 12564373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation.
    Salonen AJ; Viitanen J; Lundstedt S; Ala-Opas M; Taari K; Tammela TL;
    J Urol; 2008 Sep; 180(3):915-9; discussion 919-20. PubMed ID: 18635219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Intermittent hormonal treatment in prostatic cancer].
    Zerbib M; Conquy S
    Prog Urol; 1997 Dec; 7(6):1026-7. PubMed ID: 9490134
    [No Abstract]   [Full Text] [Related]  

  • 6. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
    Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
    Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long- or short-term hormones for locally advanced prostate cancer?
    Brower V
    J Natl Cancer Inst; 2009 Dec; 101(23):1606-8. PubMed ID: 19910554
    [No Abstract]   [Full Text] [Related]  

  • 8. [Current strategies of intermittent hormone therapy in prostate cancer].
    Kaprin AD; Pavlov AIu; Ivanov SA; Gafanov RA
    Vopr Onkol; 2011; 57(2):260-4. PubMed ID: 21809677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate cancer--management of disseminated disease (intermittent androgen suppression).
    Lobel B; Richard F
    Acta Chir Iugosl; 2005; 52(4):11-2. PubMed ID: 16673586
    [No Abstract]   [Full Text] [Related]  

  • 10. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
    Calais da Silva FE; Bono AV; Whelan P; Brausi M; Marques Queimadelos A; Martin JA; Kirkali Z; Calais da Silva FM; Robertson C
    Eur Urol; 2009 Jun; 55(6):1269-77. PubMed ID: 19249153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intermittent hormone therapy: its potential in early prostate cancer and intra-epithelial neoplasia.
    Oliver RT
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():399-404. PubMed ID: 10895186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The continued debate: intermittent vs. continuous hormonal ablation for metastatic prostate cancer.
    Gleave M; Klotz L; Taneja SS
    Urol Oncol; 2009; 27(1):81-6. PubMed ID: 19111804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intermittent androgen deprivation therapy may prolong the duration of androgen dependence of well-differentiated prostate cancer.
    Kaneko Y; Maekawa S; Arakaki R; Okada Y; Terada N; Nishimura K
    Hinyokika Kiyo; 2006 Apr; 52(4):259-64. PubMed ID: 16686352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Intermittent androgen deprivation treatment of prostate cancer restarted at low level of serum prostate specific antigen: a pilot study].
    Maekawa S; Maegawa M; Ushida H; Inoue K; Kaneko Y; Ohmori K; Nishimura K
    Hinyokika Kiyo; 2001 Aug; 47(8):553-5. PubMed ID: 11579594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intermittent androgen deprivation therapy: conventional wisdom versus evidence.
    Tombal B
    Eur Urol; 2009 Jun; 55(6):1278-80. PubMed ID: 19303201
    [No Abstract]   [Full Text] [Related]  

  • 16. Hormonal therapy options for biochemical recurrence of prostate cancer after local therapy.
    Moul JW
    Mol Urol; 2000; 4(3):267-71;discussion 273. PubMed ID: 11062383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations.
    Bruchovsky N; Klotz LH; Sadar M; Crook JM; Hoffart D; Godwin L; Warkentin M; Gleave ME; Goldenberg SL
    Mol Urol; 2000; 4(3):191-9;discussion 201. PubMed ID: 11062374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen deprivation therapy and prostate cancer duration.
    Williams SG; Pickles T; Buyyounouski MK
    J Clin Oncol; 2009 Dec; 27(34):e228; author reply e229. PubMed ID: 19884533
    [No Abstract]   [Full Text] [Related]  

  • 19. Study changes how physicians treat metastatic prostate cancer: intermittent hormone therapy not as effective as continuous hormone therapy, authors say.
    Printz C
    Cancer; 2013 Sep; 119(17):3103-4. PubMed ID: 24037668
    [No Abstract]   [Full Text] [Related]  

  • 20. [Preliminary results of casodex use in patients with hormone-resistant cancer of the prostate].
    Matveev BP; Bukharkin BV
    Urologiia; 2001; (6):20-1. PubMed ID: 11785074
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.